Post by
Indicator on Dec 21, 2009 9:44am
Barely Industry Competitive :-(
MDG's results.... seem to not quite be up to Paradigms industry competitive expectation
A four-fold increase in HI titers from baseline in 58% of subjects wasobserved in the 20 mcg group. HI titers greater than 1:40 weredeveloped in 50% of the subjects in the 20 mcg group.
Paradigms expectations:
To achieve industry-competitive efficacy status in the 48-patient Phase I reporting in December, we would like to see Medicago's vaccine induce seroconversion (≥4-fold increase in HI titer) and/or seroprotection (HI titer≥1:40 or NT≥1:20) to the homologous vaccine strain in >70% of patients after 2 immunizations preferably at the 5 or 10µg doses (groups of 12 patients will be dosed at either 5, 10 or 20µg or with placebo
damn!